Regeneron Pharmaceuticals ROE - Return on Equity 2010-2025 | REGN

Regeneron Pharmaceuticals return on equity for the quarter ending March 31, 2025 was 15.48.

  • Regeneron Pharmaceuticals average return on equity for 2024 was 15.95, a 9.63% decline from 2023.
  • Regeneron Pharmaceuticals average return on equity for 2023 was 17.65, a 41.86% decline from 2022.
  • Regeneron Pharmaceuticals average return on equity for 2022 was 30.36, a 36.45% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.

Regeneron Pharmaceuticals ROE - Return on Equity 2010-2025 | REGN

  • Regeneron Pharmaceuticals average return on equity for 2024 was 15.95, a 9.63% decline from 2023.
  • Regeneron Pharmaceuticals average return on equity for 2023 was 17.65, a 41.86% decline from 2022.
  • Regeneron Pharmaceuticals average return on equity for 2022 was 30.36, a 36.45% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.